Toll Free: 1-888-928-9744

Epilepsy - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 412 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Epilepsy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Epilepsy - Pipeline Review, H1 2016', provides an overview of the Epilepsy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epilepsy
- The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
- The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Epilepsy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Epilepsy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Epilepsy Overview 12 Therapeutics Development 13 Pipeline Products for Epilepsy - Overview 13 Pipeline Products for Epilepsy - Comparative Analysis 14 Epilepsy - Therapeutics under Development by Companies 15 Epilepsy - Therapeutics under Investigation by Universities/Institutes 22 Epilepsy - Pipeline Products Glance 24 Late Stage Products 24 Clinical Stage Products 25 Early Stage Products 26 Unknown Stage Products 27 Epilepsy - Products under Development by Companies 28 Epilepsy - Products under Investigation by Universities/Institutes 37 Epilepsy - Companies Involved in Therapeutics Development 38 Acorda Therapeutics, Inc. 38 Adamas Pharmaceuticals, Inc. 39 Advicenne Pharma 40 Aeolus Pharmaceuticals, Inc. 41 Aequus Pharmaceuticals Inc. 42 Aestus Therapeutics, Inc. 43 Alexza Pharmaceuticals, Inc. 44 Anavex Life Sciences Corp. 45 Asklepios BioPharmaceutical, Inc. 46 Astellas Pharma Inc. 47 Bial - Portela & Ca, S.A. 48 BioCrea GmbH 49 Biogen, Inc. 50 Bionomics Limited 51 Biovista Inc. 52 Biscayne Pharmaceuticals, Inc. 53 Catalyst Pharmaceutical Partners, Inc. 54 Chong Kun Dang Pharmaceutical Corp. 55 D-Pharm Ltd. 56 Eisai Co., Ltd. 57 Grifols, S.A. 58 GW Pharmaceuticals Plc 59 H. Lundbeck A/S 60 Hyundai Pharmaceutical Co., Ltd. 61 INSYS Therapeutics, Inc. 62 INVENT Pharmaceuticals, Inc. 63 Iproteos S.L. 64 Johnson & Johnson 65 Knopp Biosciences LLC 66 Lipicard Technologies Limited 67 Marathon Pharmaceuticals, LLC 68 Marinus Pharmaceuticals, Inc. 69 MedGenesis Therapeutix Inc. 70 Nemus Bioscience, Inc. 71 Neurelis, Inc. 72 Neurocrine Biosciences, Inc. 73 Neuron Biopharma SA 74 Novartis AG 75 OPKO Health, Inc. 76 Pfizer Inc. 77 PharmatrophiX, Inc. 78 Promius Pharma, LLC 79 PTC Therapeutics, Inc. 80 Retrophin Inc. 81 RODES Inc. 82 Sage Therapeutics, Inc. 83 Saniona AB 84 SciFluor Life Sciences, LLC 85 SK Biopharmaceuticals Co., Ltd. 86 Sumitomo Dainippon Pharma Co., Ltd. 87 Takeda Pharmaceutical Company Limited 88 Trillium Therapeutics Inc. 89 Turing Pharmaceuticals AG 90 UCB S.A. 91 Ultragenyx Pharmaceutical Inc. 92 Upsher-Smith Laboratories, Inc. 93 Vichem Chemie Research Ltd. 94 VistaGen Therapeutics , Inc. 95 Xenon Pharmaceuticals Inc. 96 XERIS Pharmaceuticals, Inc. 97 Zogenix, Inc. 98 Zynerba Pharmaceuticals, Inc. 99 Epilepsy - Therapeutics Assessment 100 Assessment by Monotherapy Products 100 Assessment by Target 101 Assessment by Mechanism of Action 111 Assessment by Route of Administration 118 Assessment by Molecule Type 120 Drug Profiles 122 2-DG - Drug Profile 122 ADS-4101 - Drug Profile 124 ADV-6208 - Drug Profile 125 ADV-6770 - Drug Profile 126 AEOL-1114B - Drug Profile 127 AEOL-11203 - Drug Profile 128 AEOL-11207 - Drug Profile 129 alprazolam - Drug Profile 131 AMPX-0079 - Drug Profile 133 ANAVEX-273 - Drug Profile 134 ataluren - Drug Profile 136 AV-101 - Drug Profile 140 AVL-5189 - Drug Profile 142 BIS-001 - Drug Profile 143 BNP-TLE - Drug Profile 144 BPS-015 SR - Drug Profile 145 brivaracetam - Drug Profile 146 BVA-601 - Drug Profile 149 Cannabidiol - Drug Profile 150 carbamazepine - Drug Profile 152 CCG-63802 - Drug Profile 153 Cell Therapy for Central Nervous System Disorders - Drug Profile 154 CHEC-9 - Drug Profile 156 CKD-903 - Drug Profile 158 clobazam - Drug Profile 159 clobazam - Drug Profile 160 CNV-1061436 - Drug Profile 161 cosyntropin - Drug Profile 162 CPP-115 - Drug Profile 163 CUR-1916 - Drug Profile 165 diazepam - Drug Profile 166 diazepam - Drug Profile 167 diazepam - Drug Profile 169 DP-VPA - Drug Profile 170 Drug for Epilepsy - Drug Profile 172 Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders - Drug Profile 173 Epidiolex - Drug Profile 174 eslicarbazepine acetate - Drug Profile 177 everolimus - Drug Profile 181 fenfluramine hydrochloride - Drug Profile 188 fosphenytoin sodium - Drug Profile 189 ganaxolone - Drug Profile 190 Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile 192 GWP-42006 - Drug Profile 193 histamine dihydrochloride - Drug Profile 195 immune globulin (human) - Drug Profile 196 INV-170 - Drug Profile 198 IPR-131 - Drug Profile 199 IPR-96 - Drug Profile 200 IPRO-003 - Drug Profile 201 JNJ-40411813 - Drug Profile 202 KM-113 - Drug Profile 203 KM-314 - Drug Profile 204 lacosamide - Drug Profile 205 lamotrigine - Drug Profile 211 levetiracetam - Drug Profile 212 liatermin - Drug Profile 215 LM22A-4 - Drug Profile 218 lorazepam - Drug Profile 219 LSPGR-1 - Drug Profile 220 LT-4121 - Drug Profile 221 LT-4122 - Drug Profile 222 LT-4123 - Drug Profile 223 LT-4124 - Drug Profile 224 LT-4125 - Drug Profile 225 LT-4126 - Drug Profile 226 magnesium valproate hydrate - Drug Profile 227 MB-003 - Drug Profile 228 midazolam hydrochloride - Drug Profile 229 MP-101 - Drug Profile 230 MRS-5474 - Drug Profile 231 naluzotan hydrochloride - Drug Profile 232 NB-23R1 - Drug Profile 233 NGT-168 - Drug Profile 234 NH-34 - Drug Profile 235 NRP-2945 - Drug Profile 236 NST-0037 - Drug Profile 238 NST-0076 - Drug Profile 239 Oligonucleotide for Dravet Syndrome - Drug Profile 240 perampanel - Drug Profile 241 pregabalin - Drug Profile 244 propofol hemisuccinate - Drug Profile 246 SAGE-217 - Drug Profile 247 SAGE-689 - Drug Profile 248 SCT-66 - Drug Profile 249 selurampanel - Drug Profile 250 sepranolone - Drug Profile 251 SF-0034 - Drug Profile 254 SGE-872 - Drug Profile 255 simvastatin - Drug Profile 256 Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 257 Small Molecule 2 for Epilepsy - Drug Profile 258 Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 259 Small Molecule 3 for Epilepsy - Drug Profile 260 Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 261 Small Molecule 4 for Epilepsy - Drug Profile 262 Small Molecule for Epilepsy - Drug Profile 263 Small Molecule for Epilepsy - Drug Profile 264 Small Molecule for Epilepsy - Drug Profile 265 Small Molecule for Stroke and Epilepsy - Drug Profile 266 Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile 267 Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy - Drug Profile 268 Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders - Drug Profile 269 Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 270 Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 271 Small Molecules 1 for Epilepsy - Drug Profile 272 Small Molecules 2 for Epilepsy - Drug Profile 273 Small Molecules 3 for Epilepsy - Drug Profile 274 Small Molecules 4 for Epilepsy - Drug Profile 275 Small Molecules for CNS Disorders - Drug Profile 276 Small Molecules for Epilepsy - Drug Profile 277 Small Molecules for Seizures - Drug Profile 278 Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS - Drug Profile 279 Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 280 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 281 Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 283 Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 284 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 285 Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile 286 Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile 287 sulthiame - Drug Profile 288 TAK-935 - Drug Profile 289 TF-0081 - Drug Profile 290 TG-4155 - Drug Profile 291 topiramate - Drug Profile 292 TRP-001 - Drug Profile 293 TUR-004 - Drug Profile 294 TUR-005 - Drug Profile 295 UCB-0942 - Drug Profile 296 UX-007 - Drug Profile 297 VAD-1 - Drug Profile 299 VAD-2 - Drug Profile 300 VB-3323 - Drug Profile 301 VID-45110 - Drug Profile 302 VU-0456810 - Drug Profile 303 YKP-3089 - Drug Profile 304 Z-944 - Drug Profile 306 ZYN-002 - Drug Profile 307 Epilepsy - Recent Pipeline Updates 308 Epilepsy - Dormant Projects 384 Epilepsy - Discontinued Products 393 Epilepsy - Product Development Milestones 395 Featured News & Press Releases 395 Appendix 401 Methodology 401 Coverage 401 Secondary Research 401 Primary Research 401 Expert Panel Validation 401 Contact Us 401 Disclaimer 402
List of Tables
Number of Products under Development for Epilepsy, H1 2016 23 Number of Products under Development for Epilepsy - Comparative Analysis, H1 2016 24 Number of Products under Development by Companies, H1 2016 26 Number of Products under Development by Companies, H1 2016 (Contd..1) 27 Number of Products under Development by Companies, H1 2016 (Contd..2) 28 Number of Products under Development by Companies, H1 2016 (Contd..3) 29 Number of Products under Development by Companies, H1 2016 (Contd..4) 30 Number of Products under Development by Companies, H1 2016 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H1 2016 33 Comparative Analysis by Late Stage Development, H1 2016 34 Comparative Analysis by Clinical Stage Development, H1 2016 35 Comparative Analysis by Early Stage Development, H1 2016 36 Comparative Analysis by Unknown Stage Development, H1 2016 37 Products under Development by Companies, H1 2016 38 Products under Development by Companies, H1 2016 (Contd..1) 39 Products under Development by Companies, H1 2016 (Contd..2) 40 Products under Development by Companies, H1 2016 (Contd..3) 41 Products under Development by Companies, H1 2016 (Contd..4) 42 Products under Development by Companies, H1 2016 (Contd..5) 43 Products under Development by Companies, H1 2016 (Contd..6) 44 Products under Development by Companies, H1 2016 (Contd..7) 45 Products under Development by Companies, H1 2016 (Contd..8) 46 Products under Investigation by Universities/Institutes, H1 2016 47 Epilepsy - Pipeline by Acorda Therapeutics, Inc., H1 2016 48 Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 49 Epilepsy - Pipeline by Advicenne Pharma, H1 2016 50 Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016 51 Epilepsy - Pipeline by Aequus Pharmaceuticals Inc., H1 2016 52 Epilepsy - Pipeline by Aestus Therapeutics, Inc., H1 2016 53 Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H1 2016 54 Epilepsy - Pipeline by Anavex Life Sciences Corp., H1 2016 55 Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2016 56 Epilepsy - Pipeline by Astellas Pharma Inc., H1 2016 57 Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H1 2016 58 Epilepsy - Pipeline by BioCrea GmbH, H1 2016 59 Epilepsy - Pipeline by Biogen, Inc., H1 2016 60 Epilepsy - Pipeline by Bionomics Limited, H1 2016 61 Epilepsy - Pipeline by Biovista Inc., H1 2016 62 Epilepsy - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 63 Epilepsy - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 64 Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 65 Epilepsy - Pipeline by D-Pharm Ltd., H1 2016 66 Epilepsy - Pipeline by Eisai Co., Ltd., H1 2016 67 Epilepsy - Pipeline by Grifols, S.A., H1 2016 68 Epilepsy - Pipeline by GW Pharmaceuticals Plc, H1 2016 69 Epilepsy - Pipeline by H. Lundbeck A/S, H1 2016 70 Epilepsy - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 71 Epilepsy - Pipeline by INSYS Therapeutics, Inc., H1 2016 72 Epilepsy - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 73 Epilepsy - Pipeline by Iproteos S.L., H1 2016 74 Epilepsy - Pipeline by Johnson & Johnson, H1 2016 75 Epilepsy - Pipeline by Knopp Biosciences LLC, H1 2016 76 Epilepsy - Pipeline by Lipicard Technologies Limited, H1 2016 77 Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016 78 Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 79 Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H1 2016 80 Epilepsy - Pipeline by Nemus Bioscience, Inc., H1 2016 81 Epilepsy - Pipeline by Neurelis, Inc., H1 2016 82 Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H1 2016 83 Epilepsy - Pipeline by Neuron Biopharma SA, H1 2016 84 Epilepsy - Pipeline by Novartis AG, H1 2016 85 Epilepsy - Pipeline by OPKO Health, Inc., H1 2016 86 Epilepsy - Pipeline by Pfizer Inc., H1 2016 87 Epilepsy - Pipeline by PharmatrophiX, Inc., H1 2016 88 Epilepsy - Pipeline by Promius Pharma, LLC, H1 2016 89 Epilepsy - Pipeline by PTC Therapeutics, Inc., H1 2016 90 Epilepsy - Pipeline by Retrophin Inc., H1 2016 91 Epilepsy - Pipeline by RODES Inc., H1 2016 92 Epilepsy - Pipeline by Sage Therapeutics, Inc., H1 2016 93 Epilepsy - Pipeline by Saniona AB, H1 2016 94 Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H1 2016 95 Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 96 Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 97 Epilepsy - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 98 Epilepsy - Pipeline by Trillium Therapeutics Inc., H1 2016 99 Epilepsy - Pipeline by Turing Pharmaceuticals AG , H1 2016 100 Epilepsy - Pipeline by UCB S.A., H1 2016 101 Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2016 102 Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H1 2016 103 Epilepsy - Pipeline by Vichem Chemie Research Ltd., H1 2016 104 Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H1 2016 105 Epilepsy - Pipeline by Xenon Pharmaceuticals Inc., H1 2016 106 Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H1 2016 107 Epilepsy - Pipeline by Zogenix, Inc., H1 2016 108 Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 109 Assessment by Monotherapy Products, H1 2016 110 Number of Products by Stage and Target, H1 2016 112 Number of Products by Stage and Mechanism of Action, H1 2016 122 Number of Products by Stage and Route of Administration, H1 2016 129 Number of Products by Stage and Molecule Type, H1 2016 131 Epilepsy Therapeutics - Recent Pipeline Updates, H1 2016 318 Epilepsy - Dormant Projects, H1 2016 394 Epilepsy - Dormant Projects (Contd..1), H1 2016 395 Epilepsy - Dormant Projects (Contd..2), H1 2016 396 Epilepsy - Dormant Projects (Contd..3), H1 2016 397 Epilepsy - Dormant Projects (Contd..4), H1 2016 398 Epilepsy - Dormant Projects (Contd..5), H1 2016 399 Epilepsy - Dormant Projects (Contd..6), H1 2016 400 Epilepsy - Dormant Projects (Contd..7), H1 2016 401 Epilepsy - Dormant Projects (Contd..8), H1 2016 402 Epilepsy - Discontinued Products, H1 2016 403 Epilepsy - Discontinued Products (Contd..1), H1 2016 404


List of Figures
Number of Products under Development for Epilepsy, H1 2016 23 Number of Products under Development for Epilepsy - Comparative Analysis, H1 2016 24 Number of Products under Development by Companies, H1 2016 25 Number of Products under Investigation by Universities/Institutes, H1 2016 32 Comparative Analysis by Late Stage Development, H1 2016 34 Comparative Analysis by Clinical Stage Development, H1 2016 35 Comparative Analysis by Early Stage Products, H1 2016 36 Assessment by Monotherapy Products, H1 2016 110 Number of Products by Top 10 Targets, H1 2016 111 Number of Products by Stage and Top 10 Targets, H1 2016 111 Number of Products by Top 10 Mechanism of Actions, H1 2016 121 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 121 Number of Products by Top 10 Routes of Administration, H1 2016 128 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 128 Number of Products by Molecule Types, H1 2016 130 Number of Products by Stage and Molecule Types, H1 2016 130

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify